Press Releases

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates to treat patients with neurological and psychiatric disease.

October 22, 2015

AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer’s Disease

Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the…

October 6, 2015

AgeneBio to Present at BIO Investor Forum 2015

BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at…

January 7, 2015

AgeneBio CEO Jerry McLaughlin to Present at Biotech Showcase 2015

BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the…